Related Experiment Video
Updated: Jul 20, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Genetically engineered mice in drug development
1Bayer Corporation, West Haven, CT 06516-4175, USA.
Abstract:
Complex metabolic diseases like type 2 diabetes (noninsulin-dependent diabetes) and obesity present a difficult challenge to pharmaceutical companies in their attempts to develop new therapies. The polygenic nature of these diseases and the influence of nongenetic factors make it difficult to identify the most critical molecular processes to target for drug development. Transgenic animal models provide an approach to evaluate specific sites in metabolic and hormone signalling pathways under physiologic (as opposed to in vitro) conditions. The advantages and limitations of using transgenic animals in drug development will be covered and an overview of recent information from transgenic studies relevant to type 2 diabetes and obesity will be given.
Insights
Transgenic animal models aid drug development for complex metabolic diseases like type 2 diabetes and obesity. These models evaluate molecular targets in physiological conditions, overcoming challenges posed by polygenic and non-genetic factors.
Area of Science:
- Pharmacology and Endocrinology
- Genetics and Molecular Biology
Background:
- Complex metabolic diseases, including type 2 diabetes and obesity, pose significant challenges for pharmaceutical drug development.
- The polygenic nature and influence of non-genetic factors complicate the identification of critical molecular targets.
- Current therapeutic strategies face limitations in addressing these multifaceted conditions.
Purpose of the Study:
- To explore the utility of transgenic animal models in understanding and developing therapies for type 2 diabetes and obesity.
- To evaluate the advantages and limitations of using transgenic animals for drug development in metabolic diseases.
- To provide an overview of recent transgenic study findings relevant to type 2 diabetes and obesity.
Main Methods:
- Utilizing transgenic animal models to investigate metabolic and hormone signaling pathways.
- Assessing molecular targets under physiological conditions within these models.
- Reviewing existing literature and data from transgenic studies.
Main Results:
- Transgenic models offer a physiological platform for evaluating drug targets.
- These models help elucidate complex molecular processes in metabolic diseases.
- Recent studies provide insights into potential therapeutic interventions.
Conclusions:
- Transgenic animal models are valuable tools in pharmaceutical research for metabolic diseases.
- They facilitate the identification and validation of novel drug targets.
- Further research using these models can accelerate the development of effective treatments for type 2 diabetes and obesity.
Related Concept Videos
In-vitro Mutagenesis
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

